Alzamend Neuro Announces Addition of Healthy Subjects to Ongoing Phase IIA Clinical Trial for AL001 in Alzheimer’s Subjects

Alzamend Neuro, Inc. announced it has dosed its first healthy adult subject in its Phase IIA multiple ascending dose study of AL001 in subjects with dementia related to Alzheimer’s.